NK NantKwest Inc.

1.24
-0.02  -2%
Previous Close 1.26
Open 1.25
Price To Book 0.8
Market Cap 121,901,745
Shares 98,307,859
Volume 74,380
Short Ratio
Av. Daily Volume 107,101
Stock charts supplied by TradingView

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

90% Disease Control with Median Overall Survival of 9.5 Months - noted - November 7, 2018.
haNK
Pancreatic cancer vaccine
Phase 1/2 ongoing.
haNK
Pancreatic cancer vaccine
80% Disease Control noted - November 7, 2018.
haNK
Triple Negative Breast Cancer (TNBC)
First dosing announced October, 2017.
haNK
Solid tumors
Phase 2 ongoing.
aNK
Merkel cell carcinoma
Phase 2 initiation announced January 9, 2018.
haNK + avelumab + N-803
Merkel cell carcinoma (MCC)
Phase 1b abstract at ASCO noted 2/8 SAEs.
haNK + other vaccines (NANT vaccine) (ASCO 2019)
Triple Negative Breast Cancer
IND clearance announced June 5, 2019.
CD19-t-haNK
B-cell lymphoma
Phase 1b data at ASCO 2019 - ORR of 58%, CR rate of 33%.
Nanatinostat (VRx-3996) and valganciclovir
Epstein-Barr Virus Associated Lymphoma
Phase 1 trial to be initiated.
PD-L1 t-haNK
Solid tumors